Member Info for Ombladon

Top 25 shareholders own 87.65% of the company

Vulpes Investment Management Pte. Ltd.

14.4%

Pentwater Capital Management LP

11.7%

Hargreaves Lansdown Asset Management Ltd.

8.3%

Unicorn Asset Management Ltd.

6.49%

Aberdeen Group Plc

5.94%

Oberon Investments Group Plc

5.42%

Sankofa Investment Management (Guernsey) Limited

4.94%

Jefferies Group LLC

3.99%

Barclays Bank PLC

3.22%

GHC Capital Markets Ltd.

3.05%

Trafalgar Capital Management (HK) Limited

3.04%

James Brearley & Sons Ltd.

2.72%

Killik Asset Management

2.08%

Arbuthnot Latham & Co., Limited

1.96%

HBOS Investment Fund Managers Limited

1.65%

Zeus Capital Limited

1.63%

Chelverton Asset Management Limited

1.32%

IG Group Holdings plc

1.01%

TrinityBridge Limited

0.9%

Fidelity International Ltd

0.83%

Raymond James Wealth Management Limited

0.74%

HSBC Global Asset Management (UK) Limited

0.62%

As of May 2026, the shareholder structure of Oxford BioDynamics PLC (OBD) has undergone significant shifts due to recent equity raises and the substantial dilution of shares (which grew by over 100% in the last year). 

The top 25 shareholders currently control approximately 87.65% of the company

Ownership by Category

The company’s register is heavily dominated by institutional money, with a relatively small "free float" held by the general public compared to other AIM-listed stocks.

• Institutions: ~70.0% 

• Hedge Funds: ~26.1% 

• Individual Insiders: ~1.44% 

• General Public (Retail): ~1.41%

Strategic Developments

• Vulpes' Dominance: As the largest shareholder (14.4%), Vulpes continues to exert significant influence. This was solidified on April 15, 2026, with the appointment of Martin Diggle (co-founder of Vulpes) to the Board as a Non-Executive Director. 

• High Concentration: The fact that the top 25 holders own nearly 88% of the company indicates a very "tight" register, which can lead to higher volatility in the share price when these large blocks are traded. 

• Dilution: It is worth noting that while these percentages represent the current state, the total shares outstanding now exceed 4.29 billion, following multiple funding rounds to support the commercial rollout of their EpiSwitch® tests.

We might get news soon 🙌

That was Chatgpt sorry, if you have accurate figures feel free to share

OBD’s Profit Per Test

According to OBD’s fiscal year 2025 data, the company operates with a Gross Profit Margin of approximately 47.7%. 

If we assume the wholesale price OBD receives is £500:

• Cost of Goods Sold (COGS): ~£261 (This covers the lab processing, chemicals, and the physical kit).

• Gross Profit per Test: ~£239

0.0040p my mistake

Ignore the rns part

Here’s a minor recap of what they’ve just announced:

- A breakthrough test backed by Big Pharma (Pfizer)

- An impressive 94% accuracy rate, a huge leap from the current 55% standard

- A cutting-edge AI-powered product, putting them at the forefront of medtech innovation in 2025

- high accuracy blood test to diagnose Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (ME/CFS) 96% accuracy

What this tells me. This isn't a company that's done. This is a company on the verge of something big. A global cancer test, supported by one of the largest names in the industry, with state-of-the-art technology at its core? That’s the kind of setup investors dream about.

The share price has been hammered in recent years, but that only amplifies the upside potential from here. With this kind of news, a major rerating could be just around the corner.

Of course, always DYOR - but if you're looking for a high-upside play in the AI + healthcare space, this might be the one to watch very closely.

Just a couple of years ago, this stock was trading at around £1.07. It then slid to around 40pish as many wrote the company off entirely. But yesterday’s RNS completely flips that narrative and it could mark the beginning of a major turnaround.

Here’s a minor recap of what they’ve just announced:

- A breakthrough test backed by Big Pharma (Pfizer)

- An impressive 94% accuracy rate, a huge leap from the current 55% standard

- A cutting-edge AI-powered product, putting them at the forefront of medtech innovation in 2025

- high accuracy blood test to diagnose Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (ME/CFS) 96% accuracy

What this tells me. This isn't a company that's done. This is a company on the verge of something big. A global cancer test, supported by one of the largest names in the industry, with state-of-the-art technology at its core? That’s the kind of setup investors dream about.

The share price has been hammered in recent years, but that only amplifies the upside potential from here. With this kind of news, a major rerating could be just around the corner.

Of course, always DYOR - but if you're looking for a high-upside play in the AI + healthcare space, this might be the one to watch very closely.

Https://www.uea.ac.uk/about/news/article/revolutionary-blood-test-for-me-chronic-fatigue-unveiled-1

NDA’s*

Jono44 directors cannot buy because of the NDS’s

@GoldenGod don’t be a nincompoop; take my advice and invest some money in VLRM as is a good entry point and with the profits , go and find yourself a good therapist/psychologist and have some therapy to heal your trauma as life is to good and precious . Its been 3 years, its time to move on…

Did UPL not do a crazy move a few years ago from something around this level after some good news?